uniQure (NASDAQ:QURE) Given "Buy" Rating at HC Wainwright

Key Points

• uniQure has received a "Buy" rating from HC Wainwright with a target price of $70.00, suggesting a potential upside of 75.44% from its previous close.
• Several analysts have reaffirmed their ratings for uniQure, with an average consensus target price of $37.45 and a majority of ratings categorized as "Buy."
• uniQure's stock has been volatile, trading as high as $42.71 and as low as $4.45 over the past year, with a market capitalization of $2.19 billion.

uniQure (NASDAQ:QURE - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $70.00 price target on the biotechnology company's stock. HC Wainwright's price objective would indicate a potential upside of 75.44% from the stock's previous close.

QURE has been the topic of several other reports. Chardan Capital reaffirmed a "buy" rating and issued a $35.00 price target on shares of uniQure in a research report on Monday, September 8th. Cantor Fitzgerald set a $47.00 price objective on uniQure in a report on Wednesday, July 30th. Mizuho raised uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 price objective on the stock in a report on Thursday, August 14th. Finally, Wall Street Zen raised uniQure from a "sell" rating to a "hold" rating in a report on Saturday, August 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $37.45.

uniQure Stock Performance

Shares of NASDAQ QURE traded up $26.24 during trading hours on Wednesday, hitting $39.90. 29,667,772 shares of the stock were exchanged, compared to its average volume of 1,495,028. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The company's 50 day moving average is $15.24 and its 200 day moving average is $14.09. The firm has a market capitalization of $2.19 billion, a P/E ratio of -10.23 and a beta of 0.14. uniQure has a one year low of $4.45 and a one year high of $42.71.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.20. The company had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, research analysts expect that uniQure will post -3.75 EPS for the current year.

Institutional Investors Weigh In On uniQure

Large investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new stake in shares of uniQure in the first quarter worth about $2,562,000. OMERS ADMINISTRATION Corp bought a new stake in shares of uniQure in the first quarter worth about $152,000. Assenagon Asset Management S.A. increased its holdings in shares of uniQure by 355.2% in the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock worth $3,550,000 after acquiring an additional 261,323 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of uniQure in the first quarter worth about $3,218,000. Finally, XTX Topco Ltd increased its holdings in shares of uniQure by 127.3% in the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company's stock worth $392,000 after acquiring an additional 20,720 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.